A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Condition:   Solid Cancers
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Interferon alfa-2b;   Drug: Ipilimumab;   Drug: Obinutuzumab;   Drug: PEG-interferon alfa-2a
Sponsor:   Hoffmann-La Roche
Recruiting - verified April 2017

http://ift.tt/2oz58ir